AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05081115 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ABCDE-Stress Echo
Description: Each laboratory will adopt the preferred Echo stress among physical pharmacologic or pacing stress according to guidelines recommendations. Pharmacologic testing will be with dobutamine or vasodilators (dipyridamole, adenosine or regadenoson) according to physician preferences, patients' contraindications, local availability and cost. Pacing stress can be performed with transesophageal or with external permanent pacemaker. A standardized format with the ABCDE protocol will be followedl. Step D is easy with vasodilator, less easy with dobutamine, not easy and less feasible - impossible with (peak or post) treadmill exercise. Our recommendation is to use semi-supine exercise, capturing coronary flow signal in early or intermediate stages when most flow increases and feasibility is still high. When treadmill is used, step D is skipped; if information is deemed important, a vasodilator test can be performed at 30' after the end of exercise focused on CFVR and heart rate response.
Study NCT05080530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Effect of Vitamin D on diabetic neuropathy symptoms
Study NCT04833114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin 1.8 mg/kg will be administered intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
Study NCT04833114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mabthera
Description: Rituximab (Mabthera/Rituxan®) will be administered as per local practice at a dose of 375 mg/m2 intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
Study NCT04833114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mabthera
Description: Rituximab (Mabthera/Rituxan®) will be administered as per local practice at a dose of 375 mg/m2 intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
Study NCT04833114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 5000 mg/m² will be administered i.v. over a 24 hr period starting on cycle Day 2.
Study NCT01391975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active ultrasound surveillance of fistula and proactive treatment of stenosis
Description: Regular duplex ultrasound assessment of fistula from time of creation until 6 months post procedure with referral of all haemodynamically significant stenoses to further imaging and treatment
Study NCT06447090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome
Description: Veneclatra (VEN) 400 mg/d (reduced to 100 mg when combined with an azole), d1-7; Mitoxantrone Liposomal 30 mg/m2, d1; Cytosine arabinoside(Ara-C) 100 mg/m2/d, d1-7; Cyclophosphamide (CTX) 400 mg/m2/d, d2, 5); After 1 day of rest, cryopreserved donor stem cells MNC1-2X10\^8 /kg infusion, add low-dose (25 mg Bid) and short-course treatment (stop 2-3 weeks after DLI) oral cyclosporine (CSA) to prevent graft-versus-host disease (GVHD) 3 days before cryopreserved stem cell infusion.
Study NCT04833114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Ifosfamide 5000 mg/m² will be administered i.v. over a 24 hr period starting on cycle Day 2.
Study NCT04833114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 max 800 mg will be administered i.v. on cycle Day 2.
Study NCT04833114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5 max 800 mg will be administered i.v. on cycle Day 2.
Study NCT04833114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m² will be administered i.v. on cycle Days 1, 2 and 3.
Study NCT04833114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100 mg/m² will be administered i.v. on cycle Days 1, 2 and 3.
Study NCT05525650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: House Dust Mite Extract, Dermatophagoides Farinae
Description: \[Group 1\] Group A receives 100 PAU at week 1 and 200 PAU at week 2 as the induction phase.~200 PAU is administered for 3 to 16 weeks as a maintenance phase.~Group B (placebo group) is the placebo arm of group A.~\[Group 2\] As the induction phase, group C received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, and 400 PAU at week 4.~As the maintenance phase, 400 PAU is administered for 5 to 16 weeks.~Group D (placebo) is the placebo group in Group C.~\[Group 3\] As the induction phase, group E received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, 400 PAU at week 4, 600 PAU at week 5, and 800 PAU at week 6.~As the maintenance phase, 800 PAU is administered from 7 to 16 weeks.~Group F (placebo) is the placebo arm of group E.
Study NCT05525650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: House Dust Mite Extract, Dermatophagoides Farinae
Description: \[Group 1\] Group A receives 100 PAU at week 1 and 200 PAU at week 2 as the induction phase.~200 PAU is administered for 3 to 16 weeks as a maintenance phase.~Group B (placebo group) is the placebo arm of group A.~\[Group 2\] As the induction phase, group C received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, and 400 PAU at week 4.~As the maintenance phase, 400 PAU is administered for 5 to 16 weeks.~Group D (placebo) is the placebo group in Group C.~\[Group 3\] As the induction phase, group E received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, 400 PAU at week 4, 600 PAU at week 5, and 800 PAU at week 6.~As the maintenance phase, 800 PAU is administered from 7 to 16 weeks.~Group F (placebo) is the placebo arm of group E.
Study NCT06508671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DL-3-n-butylphthalide
Description: Take butylphthalide soft capsules orally
Study NCT06508671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empty Medication Capsules
Description: Take empty medication capsules orally
Study NCT05487911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: 4 weeks of active rTMS (total of up to 20 sessions)
Study NCT05081115 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SE diastolic assessment
Description: The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation, at intermediate load of exercise and/or 1- 2 min after the end of the exercise. We will also assess, at baseline, intermediate load (50 watts) and peak-post stress: end-diastolic left ventricular volume index; end-systolic left ventricular volume index; ejection fraction and both stroke volume and cardiac output (to assess conventional contractile reserve); mitral regurgitation and left ventricular outflow tract obstruction; pulmonary artery systolic pressure; B-lines; right ventricular free wall strain to assess the presence of right ventricular dysfunction; left atrial volume index; peak atrial longitudinal strain; and mitral inflow E velocity and mitral annulus e' tissue Doppler velocity; global longitudinal strain (GLS).
Study NCT06085781 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fMRI
Description: Functional Magnetic Resonance Imaging
Study NCT06085781 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oral Pimonidazole
Description: 200 mg and 300 mg tablets
Study NCT05081115 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SE Right ventricular function assessment
Description: Right ventricular function will be assessed at baseline and peak stress with variations of tricuspid annular plane systolic excursion, an index of right ventricular longitudinal function, and right ventricular fractional area change (a load-dependent index of right ventricular inlet function). To distinguish between genuine right ventricular dysfunction and/or pathological increases in pulmonary vascular load, we will combine systolic pulmonary artery pressure and right ventricular end-systolic area to calculate right ventricular end-systolic pressure-area relation. Peak systolic tricuspid annulus velocity and conventional indices of left ventricular systolic and diastolic function will also be measured at baseline and peak stress according to the standard ABCDE-FGLPR protocol. Right ventricular free wall strain combined with interventricular septum strain will be assessed. Left ventricular function, wall motion score index and E/e' at baseline and peak stress.
Study NCT05157932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talk test prescription
Description: Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on the Talk test method.
Study NCT05157932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPET prescription
Description: Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on their CPET results completed at baseline
Study NCT05081115 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SE in heart donors
Description: The examination of the heart starts with a resting transthoracic echocardiography. Exclusion criteria are: resting wall motion score index>1.0; ejection fraction \<45%; diastolic dysfunction of grade 2 or more; hemodynamically significant (moderate or higher) valve regurgitation or stenosis; severe left ventricular hypertrophy (left ventricular mass index >175 g/m2). A pharmacological SE with dipyridamole (0.84 mg/kg over 6 minutes) is recommended. The diagnostic end-points are stress-induced RWMA and abnormalities in global LVCR. All images will be analyzed as per guidelines similarly to the other projects, with emphasis on wall motion score index and LVCR based on ejection fraction and force. The hearts excluded from donation for RWMA or abnormal LVCR could however be collected for heart valve preparation and evaluated by coronary angiography and by pathological examination according to local facilities.
Study NCT04971486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Sequence Task
Description: Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear.
Study NCT06249087 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT06249087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT06249087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study NCT06249087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study NCT05369351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment+mirabegron
Description: In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.
Study NCT05369351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment
Description: Standard treatment
Study NCT05551143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LiftKit
Description: The LiftKit contains 7 tools that could assist EMS providers when lifting/moving patients. These tools are:~1. Simple Strap - A sling to lift a seated patient~2. Strap and slide stick - A strap system for raising a supine patient to a sitting posture.~3. Slip Preventer- An envelope that goes over the patients feet with high friction straps for the EMS providers to stand on that prevent the patient from sliding forward when lifted.~4. Drag Straps - straps with handles that can be clipped on tarps used to drag patients~5. The Binder Lift - a vest with handles that allow EMS providers to easily get hold of patient they need to lift.~6. Patient Turning Straps - a way to log-roll a patient that in on the floor while in a standing posture.~7. The ELK - an inflatable seat cushion that can raise a patient who in the floor to chair level
Study NCT05009758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood collection for PBMC isolation, measurement of cytokines in serum, and mass cytometry
Study NCT05009758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasosorption
Description: Nasosorptions will be applied for the collection of nasal secretions (Nasosorption FX-I, Hunt Developments (UK) Limited, Midhurst, West Sussex, United Kingdom). Under visualization, the device will be inserted into the nasal cavity and be placed along the lateral wall against the inferior turbinate. The index finger of the patient will be used to press onto the external aspects of the alar and lateral nasal cartilages to hold the device in place. After 1 minute, the devices will be removed.
Study NCT05009758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral sampling
Description: For oral sampling, saliva collection devices (SuperSAL or PureSAL, Oasis Diagnostic Corporation, USA) will be applied followed by elution. Then swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the dorsum of the tongue.
Study NCT05009758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: The bronchoscopy will be performed in the outpatient clinic of the Department of Pulmonology. Bronchial alveolar lavage (BAL): the bronchoscope is wedged in the segmental or subsegmental bronchus of the middle lobe. Up to 300 ml sterile normal saline is injected stepwise via handheld syringe and then gradually withdrawn back into the syringe. BAL fluid (BALF) will be prepared and further analyzed in the lab. Transbronchial biopsy (TBLB): performed by forceps in the lung periphery under fluoroscopy guidance. Up to 4 biopsies are taken in two different lobes of one lung with a distance of 1-2 cm to the pleura. TBLB is only performed in patients who have got not contraindications.
Study NCT05009758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal biopsy
Description: Nasal biopsies will be taken during routine endoscopy performed to score CRSwNP. Patients will receive local anesthesia and decongestants prior to obtaining the biopsy. Samples will either be embedded in OCT or processed for cellular analysis
Study NCT05009758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal sampling
Description: Swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the anterior naris and middle meatus of each nostril
Study NCT05009758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal mucosa mRNA sampling
Description: Mucosal mRNA sampling will be performed using a 10cm nasal curette (either Rhino-Probe, Arlington Scientific, USA or Cellskim, Hunt Developments, UK). Under direct visualization, the curette will be brought to lie against the mid-inferior portion of the inferior turbinate. The curette will be pressed against the mucosal surface moved outwards 2-3 times. This motion will be repeated 2-3 times to ensure good sample collection. This curette and technique have been shown to cause no significant discomfort to patients and thus it has the advantage of no requirement for local anesthetics.
Study NCT05333861 — intervention group
Intervention type: DRUG
Intervention: hetrombopag
Description: According to prescription
Study NCT05749315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Play Based Therapy
Description: Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
Study NCT05749315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Communication Training
Description: Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
Study NCT05613023 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Stereotactic Body Radiotherapy
Study NCT05613023 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiotherapy
Study NCT04921228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback
Description: * 5 days of 3-min HRV readings to establish baseline HRV~* After meeting with study personnel to review HRV biofeedback (BF) practice with the app, participants will be asked to begin HRV BF training for 5 min a day~* Participants will increase the length of HRV BF training by 5 min every few days until they reach 20 min a day of HRV BF training~* Participants will aim for 20 min of daily HRV BF training for 6 consecutive wks out of the 8-wk total BF training protocol~* Study personnel will follow the participants' progress with training via the online portal provided through the Optimal HRV app and have brief (15-min) check-in appts. with participants to discuss how they are experiencing HRV BF, what they find helpful, and barriers to their practice if they are having difficulties~* After completing the 8-wks of BF training (including 2 wks of 5-min titrations to the full 20-min protocol), participants will be asked to take 3-min HRV readings for 5 days to assess post-intervention HRV
Study NCT04767503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Maintence of anestheisa with propofol guided by the bispectral index in the range 40-60.
Study NCT04767503 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Desflurane
Description: Maintence of anestheisa with desflurane guided by the bispectral index in the range 40-60.
Study NCT05481489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate
Description: Atropine Sulfate 0.05% Ophthalmic Solution
Study NCT05633888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CATAMARAN SI Joint Fusion System
Description: Placement of the Catamaran Fixation Device
Study NCT04826939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFDx device and leva device
Description: Participants will use the leva device, PFDx device and undergo ultrasound measurements during pelvic floor motion to compare the three measurements.
Study NCT06400953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinetic Brain Exercises and Core Stabilization Exercises
Description: Kinetic Brain Exercise Program Kinetic brain exercises were applied to Group 1 in groups of 8-10 people, 2 days a week for 40 minutes for 8 weeks.These exercises include warm-up, main and cool-down phases. Warm-up; These are coordination-oriented movements that include 'brain buttons', 'cross crawl' and 'the thinking cap' exercises. Main phase; These are exercises that include coordination, selective attention, audio-visual focus and balance, consisting of perceptual, independent and dependent movements. Cooling phase; It aims to ensure hand-eye coordination by consisting of double doodle, throwing balls to each other and lazy 8s exercises.Exercises were selected from the kinetic brain exercise pool, modified and applied for 2-8 weeks.The exercises were done while sitting and standing, with increasing difficulty levels. The factor that made the levels difficult was the time and complexity of the incoming command. A game ball with a diameter of 7 cm was used for the exercises.